To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03943342
Title Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kerry Rogers
Indications
Therapies
Age Groups: adult | senior
Covered Countries


No variant requirements are available.